Depressive symptoms are a common feature of schizophrenia, complicate the course of recovery, and introduce a heightened risk of suicide. Tollefson et alArticle reported on an international sample of nearly 2000 patients with schizophrenia or related disorders. Over half had at least moderate depression. The novel antipsychotic agent, olanzapine, outperformed the standard neuroleptic, haloperidol, on a series of mood-related measures. These findings suggest that symptoms of depression within schizophrenia, including suicidal ideation, are treatment responsive.